Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study

Shervin Ziabakhsh-Tabary, Rozita Jalalian, Farzad Mokhtari-Esbuie, Mohammad Reza Habibi, Shervin Ziabakhsh-Tabary, Rozita Jalalian, Farzad Mokhtari-Esbuie, Mohammad Reza Habibi

Abstract

Background: Erythropoietin (EPO) is known as a regulating hormone for the production of red blood cells, called erythropoiesis. Some studies have shown that EPO exerts some non-hematopoietic protective effects on ischemia-reperfusion injuries in myocytes. Using echocardiography, we evaluated the effect of EPO infusion on reducing ischemia-reperfusion injuries and improvement of the cardiac function shortly after coronary artery bypass graft surgery (CABG).

Methods: Forty-three patients were recruited in this study and randomly divided into two groups: the EPO group, receiving standard medication and CABG surgery plus EPO (700 IU/kg), and the control group, receiving standard medication and CABG surgery plus normal saline (10 cc) as placebo. The cardiac function was assessed through echocardiography before as well as at 4 and 30 days after CABG.

Results: Echocardiography indicated that the ejection fraction had no differences between the EPO and control groups at 4 days (47.05±6.29 vs. 45.90±4.97; P=0.334) and 30 days after surgery (47.27±28 vs. 46.62±5.7; P=0.69). There were no differences between the EPO and control groups in the wall motion score index at 4 (P=0.83) and 30 days after surgery (P=0.902). In the EPO group, there was a reduction in left ventricular end-systolic and end-diastolic diameters (LVESD and LVEDD, respectively), as compared to the control group.

Conclusion: Our results indicated that perioperative exogenous EPO infusion could not improve the ventricular function and wall motion index in the immediate post-CABG weeks. Nevertheless, a reduction in LVEDD and LVESD at 4 days and 30 days after CABG in the EPO group, by comparison with the control group, suggested that EPO correlated with a reduction in the remodeling of myocytes and reperfusion injuries early after CABG.

Trial registration number: 138809102799N1.

Keywords: Coronary artery bypass graft; Erythropoietin; Ischemia; Reperfusion injury.

Figures

Figure 1
Figure 1
The patient’s consort flow chart is illustrated above.
Figure 2
Figure 2
Wall motion score index before and after coronary artery bypass graft surgery in both groups.

References

    1. Adamson JW, Longo DL. Anemia and polycythemia. Hematologic alterations. In: Fauci A, Braunwald E, Kasper D, editors. Harrison’s principle of internal medicine. 17th ed. Vol. 2. New York: McGraw Hill; 2008. pp. 329–37.
    1. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000;97:10526–31. doi: 10.1073/pnas.97.19.10526. PubMed PMID: 10984541; PubMed Central PMCID: PMC27058.
    1. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19: 348–55. doi: 10.1093/ndt/gfg547. PubMed PMID: 14736958.
    1. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659–64. doi: 10.1073/pnas.152321399. PubMed PMID: 12130665; PubMed Central PMCID: PMC125005.
    1. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem. 2000;275:39754–61. doi: 10.1074/jbc.M004999200. PubMed PMID: 10995753.
    1. Westenbrink BD, de Boer, Voors AA, van Gilst, van Veldhuisen. Anemia in chronic heart failure: etiology and treatment options. Curr Opin Cardiol. 2008;23:141–7. doi: 10.1097/HCO.0b013e3282f43025. PubMed PMID: 18303527.
    1. Mudalagiri NR, Mocanu MM, Di Salvo, Kolvekar S, Hayward M, Yap J, et al. Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and and ERK1/2 activation. Br J Pharmacol. 2008;153:50–6. doi: 10.1038/sj.bjp.0707461. PubMed PMID: 17952111; PubMed Central PMCID: PMC2199395.
    1. Schoemaker R, Lipsic E, van der, van der, van Gilst, van Veldhuisen, et al. EPO-induced neovascularization in heart failure rats. Journal of Molecular and Cellular Cardiology. 2006;40:948. doi:10.1016/j.yjmcc.2006.03.092.
    1. Westenbrink BD, Lipsic E, van der, van der, Oeseburg H, Du Marchie, et al. Erythropoietin improves cardiac function through Endothelial progenitor cell and vascular Endothelial growth factor mediated neovascularization. Eur Heart J. 2007;28:2018–27. doi: 10.1093/eurheartj/ehm177. PubMed PMID: 17576662.
    1. Westenbrink BD, Oeseburg H, Kleijn L, van der, Belonje AM, Voors AA, et al. Erythropoietin stimulates normal Endothelial progenitor cell-mediated Endothelial turnover, but attributes to neovascularization only in presence of local ischemia. Cardiovasc Drugs Ther. 2008;22:265–74. doi: 10.1007/s10557-008-6094-y. PubMed PMID: 18327705.
    1. Elhendy A, Cornel JH, van Domburg, Bax JJ, Roelandt JR. Effect of coronary artery bypass surgery on myocardial perfusion and ejection fraction response to inotropic stimulation in patients without improvement in resting ejection fraction. Am J Cardiol. 2000;86:490–4. PubMed PMID: 11009263.
    1. Morrow D, Boden W. Stable ischemic heart diseases. In: Bonow R, Mann D, Zipes D, Libby P, editors. Braunwald’s Heart Disease. 9th ed. Philadelphia: Elsevier Saunders; 2009. pp. 1210–69.
    1. Weman SM, Karhunen PJ, Penttilä A, Järvinen AA, Salminen US. Reperfusion injury associated with one-fourth of deaths after coronary artery bypass grafting. Ann Thorac Surg. 2000;70:807–12. doi: 10.1016/S0003-4975(00)01638-6. PubMed PMID: 11016314.
    1. Lalu MM, Pasini E, Schulze CJ, Ferrari-Vivaldi M, Ferrari-Vivaldi G, Bachetti T, et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J. 2005;26:27–35. doi: 10.1093/eurheartj/ehi007. PubMed PMID: 15615796.
    1. Doue T, Ohtsuki K, Ogawa K, Ueda M, Azuma A, Saji H, et al. Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: assessment of infarct size with 99mTc-annexin V. J Nucl Med. 2008;49:1694–700. doi: 10.2967/jnumed.107.050260. PubMed PMID: 18794258.
    1. Javadi L, Pezeshkian M, Afrasiabi A, Garjani A, Roshangar L, Golmohammadi Z, et al. Erythropoietin Prevention effect on Induced Apoptosis by Ischemia-Reperfusion in Myocytes of Rat. J CardiovascThorac Res. 2010;2:1–7.
    1. Shen Y, Wang Y, Li D, Wang C, Xu B, Dong G, et al. Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. Transplant Proc. 2010;42:1595–7. doi: 10.1016/j.transproceed.2009.11.050. PubMed PMID: 20620481.
    1. Lipsic E, van der, Voors AA, Westenbrink BD, van den, de Boer, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006;20:135–41. doi: 10.1007/s10557-006-7680-5. PubMed PMID: 16761193.
    1. Mocini D, Muso P, Guendouz E, De Marco, Mele L, Cini R, et al. Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery. Perfusion. 2008;23:187–92. doi: 10.1177/0267659108097627. PubMed PMID: 19029270.
    1. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003;100:4802–6. doi: 10.1073/pnas.0630444100. PubMed PMID: 12663857.
    1. Paschos N, Lykissas MG, Beris AE. The role of erythropoietin as an inhibitor of tissue ischemia. Int J Biol Sci. 2008;4:161–8. doi:10.7150/ijbs.4.161. PubMed PMID: 18566695; PubMed Central PMCID: PMC2430987.
    1. Søraas CL, Larstorp AC, Mangschau A, Tønnessen T, Kjeldsen SE, Bjørnerheim R. Echocardiographic demonstration of improved myocardial function early after coronary artery bypass graft surgery. Interact Cardiovasc Thorac Surg. 2011;12:946–51. doi: 10.1510/icvts.2010.260414. PubMed PMID: 21422155.
    1. Murphy NF, O’Loughlin C, Ledwidge M, McCaffrey D, McDonald K. Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients. Eur J Heart Fail. 2007;9:1196–204. doi: 10.1016/j.ejheart.2007.10.001. PubMed PMID: 18039520.
    1. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44–51. doi: 10.1161/01.CIR.76.1.44. PubMed PMID: 3594774.
    1. Morales MA, Startari U, Rossi G, Panchetti L, Rossi A, Piacenti M. Reverse left ventricular remodeling is more likely in non ischemic cardiomyopathy patients upgraded to biventricular stimulation after chronic right ventricular pacing. Cardiovasc Ultrasound. 2011;9:41. doi: 10.1186/1476-7120-9-41. PubMed PMID: 22177469; PubMed Central PMCID: PMC3265428.
    1. Chen TM, Li J, Liu L, Fan L, Li XY, Wang YT, et al. Effects of heme oxygenase-1 upregulation on blood pressure and cardiac function in an animal model of hypertensive myocardial infarction. Int J Mol Sci. 2013;14:2684–706. doi: 10.3390/ijms14022684. PubMed PMID: 23358254; PubMed Central PMCID: PMC3588009.
    1. Knapp M, Musial WJ, Lisowska A, Hinrle T. Myocardial contractility improvement after coronary artery by-pass grafting in a 1-year observation: The role of myocardial viability assessment. Cardiol J. 2007;14:246–51. PubMed PMID: 18651468.
    1. Kapur A, Qureshi AC, Gallagher S, Finlay M, Malik IS, Mayet J, et al. Myocardial function may improve equally in diabetic patients following both multivessel percutaneous coronary intervention and coronary artery bypass grafting: results from a CARDia trial substudy. Eur J Echocardiogr. 2011;12:904–9. doi: 10.1093/ejechocard/jer149. PubMed PMID: 21900302.
    1. Awan MA, Khan A, Siddiqi TA, Hussain A, Rabbi F, Tasneem H. Early effects of coronary artery bypass grafting on left ventricular regional wall motion abnormalities. J Coll Physicians Surg Pak. 2007;17:3–7. doi:01.2007/JCPSP.0307. PubMed PMID: 17204210.
    1. Lorusso R, La Canna, Ceconi C, Borghetti V, Totaro P, Parrinello G, et al. Long-term results of coronary artery bypass grafting procedure in the presence of left ventricular dysfunction and hibernating myocardium. Eur J Cardiothorac Surg. 2001;20:937–48. doi: 10.1016/S1010-7940(01)00945-9. PubMed PMID: 11675178.
    1. Lipsic E, van der, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473–9. doi: 10.1097/01.fjc.0000140209.04675.c3. PubMed PMID: 15454856.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa